Prevalence of HLA-B*1502 is high among Han Chinese. Patients carrying HLA-B*1502 are at strongly increased risk for life treatening carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). Genetic testing is highly recommended before carbamazepine is administered to patients from China, due to high risk for carrying HLA-B*1502. The first report stated (Han-Chinese living in Taiwan) that the odds ratio (if positive for HLA-B*1502) for developing carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis was 2504 (95% CI: 126−49,522) (Ferrel, 2008). Later a systematic review yielded a summary odds ratio of 115.32; (95% CI, 18.17-732.13) among Han-Chinese. (Tangamornsuksan et al., 2013).

See also: Special topics.

Han-Chinese patients (major depressive disorder) with the 5-HTTLPR l/l genotype had a significantly better response to fluoxetine when compared with s allele carriers, as evaluated on the basis of Hamilton Depression Rating Scale-score percentage change: total (P = 0.013), core (P = 0.011), and psychic-anxiety (P = 0.005) and somatic-anxiety (P = 0.002) , confirming previous western reports.
(N= 121 patients with major depressive disorder; Han-Chinese sample population of Taiwan)
(Yu et al., 2002)

There is an association (odds ratio: 4.98, 95% confidence interval 1.43–17.28; P < 0.05) between the human leukocyte antigen HLA-B*1502 allele and lamotrigine-induced Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in Han Chinese subjects. The HLA-B*1502 allele was present in 33.3% of lamotrigine-induced SJS/TEN patients and in only 9.4% of lamotrigine tolerant patients (Zeng et al. 2015).